Amrit Ecosystem puts patients at the heart of the solution


AI and blockchain

leveraging life science AI at scale to build a decentralized royalty portfolio, governed by the DAO


through a DAO Paradigm for Decentralized Drug Discovery

Decentralized Drug Discovery

using a highly secure, federated ecosystem for all the industry stakeholders


Receive tokens for providing data
Can donate tokens
Can buy in-app services with tokens, e.g. second opinion, digital therapeutics


Run surveys using tokens
Pay tokens for participation
License data in & out


Receive donations
Facilitate discovery & other programs for patients

Regulators, Insurers

Run objective analysis and surveys to build the best and safest auditing and control system

Digital Therapeutics

Platform with existing reach for individual applications
Complete package for patients – no piecemeal


Can buy tokens on the secondary exchange and profit from the value increase

An ecosystem to offer several services to different stakeholders that are fully integrated in the disease specific apps

Second Opinion

Patients receive second opinion from Health Care Professionals.

Research Projects

Patients license their data to research projects/ virtual studies run by pharma and CROs.

Additional in-app services

Patients, physicians and hospitals access digital therapeutics and resources offered by service providers.

All services will be paid via Utility Token Amrit

Drug Discovery Programs
Amrit has its own pancreatic cancer drug discovery program for the past 3 years
PALAS | PAncreatic cancer Liquid biospies Analysis Study

Non-interventional Biomarker Study to Evaluate Molecular Diagnostic Methods for Improving Future Treatment Approaches in Pancreatic Cancer Patients

We will find a cure, augmenting our patented AI with patients’ support

AI-powered R&D together with Real World Data, significantly increases success, saving time and money

Principal Investigators:
Prof. Dr. rer. nat. Dr. med. Jürgen Scheele & Dr. med. Werner Seiz

Why? PaCa is a death warrant

deaths per year 466,000

5-year survival rate is 3%

no improvement since 1971

Our highly respected Advisory Board unites internationally well-respected pancreatic cancer experts

Prof. Dr. Volker Heinemann
  • Prof. Heinemann is one of the leading researchers for Pancreatic Cancer in Germany.
  • Medical specialist in oncology and Director of the Comprehensive Cancer Center in Munich.
  • Besides his role as principal investigator in translational cancer medicine, he is the Head of the Munich Interdisciplinary Tumor Board.
Prof. Juergen Scheele

Chief Medical Officer, Innoplexus

Former Global Clin. Dev. Leader (Merck, Roche, AmGen). 20+ yrs experience in drug development and discovery.
Prof. Dr. Michael Geissler
  • Medical Director and Chief Physician at the Klinikum Esslingen.
  • Medical Head of Karlsruhe Clinic, one of the largest Medical Centers in Germany.
  • Research at the University Hospital of Freiburg and Harvard Medical School have contributed to his international reputation of excellence.
Prof. Dr. Florian Otto
  • GI tumor specialist at the Tumor Center St.Gallen.
  • Previously the Head of the Interdisciplinary GI Tumor Center at the University of Freiburg Medical Center, the largest Medical Institution in Central Europe.
  • Prof. Otto obtained his medical degrees from the RWTH in Aachen and the University of Freiburg.
Prof. Dr. Uwe Wittel
  • Executive Attending Physician and Head of the Pancreas Center at the University of Freiburg.
  • His research focus in Pancreatic Cancer is demonstrated by an outstanding publication record at high impact journals.
  • Prof. Wittel studied medicine at the Universities of Ulm and Tübingen. His studies also led him to the University of Nebraska Medical Center.